Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian R Murphy

Showing results (101-110 of 122) with videos related to

Pageof 13
Sort By:
The Journal of Infectious Diseases|February 13, 2009
A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adultsRuth A Karron, Karen Callahan, Catherine Luke, et al.
Virology|June 27, 2002
Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzeesMario H Skiadopoulos, Sonja R Surman, Jeffrey M Riggs, et al.
Virology|November 18, 2008
Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challengeAlexander Bukreyev, Andrea Marzi, Friederike Feldmann, et al.
Vaccine|September 18, 2007
The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccinesPeter F Wright, Ruth A Karron, Robert B Belshe, et al.
International Journal of Oncology|February 4, 2010
Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trialsAminah Jatoi, Nathan R Foster, James R Egner, et al.
Journal of Virology|November 20, 2009
Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeysJoshua M DiNapoli, Baibaswata Nayak, Lijuan Yang, et al.
The American Journal of Tropical Medicine and Hygiene|November 5, 2008
Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicityJulie H McArthur, Anna P Durbin, Jennifer A Marron, et al.
Vaccine|April 17, 2014
Assurance of neuroattenuation of a live vaccine against West Nile virus: a comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4Δ30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccineOlga A Maximova, James M Speicher, Jeff R Skinner, et al.
Oncology and Therapy|July 26, 2021
A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation StatusJenna M Collins, Beth L Nordstrom, Kimmie K McLaurin, et al.
Journal of Virology|July 11, 2008
Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primatesEmmalene J Bartlett, Ann-Marie Cruz, Janice Esker, et al.
Pageof 13

Showing results (101-110 of 122) with videos related to

Sort By:
Pageof 13
The Journal of Infectious Diseases|February 13, 2009
A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adultsRuth A Karron, Karen Callahan, Catherine Luke, et al.
Virology|June 27, 2002
Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzeesMario H Skiadopoulos, Sonja R Surman, Jeffrey M Riggs, et al.
Virology|November 18, 2008
Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challengeAlexander Bukreyev, Andrea Marzi, Friederike Feldmann, et al.
Vaccine|September 18, 2007
The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccinesPeter F Wright, Ruth A Karron, Robert B Belshe, et al.
International Journal of Oncology|February 4, 2010
Older versus younger patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and stomach: a pooled analysis of eight consecutive North Central Cancer Treatment Group (NCCTG) trialsAminah Jatoi, Nathan R Foster, James R Egner, et al.
Journal of Virology|November 20, 2009
Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeysJoshua M DiNapoli, Baibaswata Nayak, Lijuan Yang, et al.
The American Journal of Tropical Medicine and Hygiene|November 5, 2008
Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicityJulie H McArthur, Anna P Durbin, Jennifer A Marron, et al.
Vaccine|April 17, 2014
Assurance of neuroattenuation of a live vaccine against West Nile virus: a comprehensive study of neuropathogenesis after infection with chimeric WN/DEN4Δ30 vaccine in comparison to two parental viruses and a surrogate flavivirus reference vaccineOlga A Maximova, James M Speicher, Jeff R Skinner, et al.
Oncology and Therapy|July 26, 2021
A Real-World Evidence Study of CDK4/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation StatusJenna M Collins, Beth L Nordstrom, Kimmie K McLaurin, et al.
Journal of Virology|July 11, 2008
Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primatesEmmalene J Bartlett, Ann-Marie Cruz, Janice Esker, et al.
Pageof 13